Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04683315 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Study acronym: PANCREAS
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: 87 to 84 Interventions: Chemoradiation (Radiation), Gemcitabine/Nab-paclitaxel Treatment Regimen (Drug), mFOLFIRINOX Treatment Regimen (Drug) to Gemcitabine/Nab-paclitaxel Treatment Regimen (Drug), mFOLFIRINOX Treatment Regimen (Drug) · Eligibility criteria expanded, about 192 words · Study arms: 8 to 2v9 Show 3 more changesShow less
    • Interventions: Chemoradiation (Radiation), Gemcitabine/Nab-paclitaxel Treatment Regimen (Drug), mFOLFIRINOX Treatment Regimen (Drug) to Gemcitabine/Nab-paclitaxel Treatment Regimen (Drug), mFOLFIRINOX Treatment Regimen (Drug)
    • Eligibility criteria expanded, about 192 words
    • Study arms: 8 to 2

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date: Jun 2026 to Dec 31, 2027 Completion date: Jun 2027 to Dec 31, 2028v8 Show 1 more changeShow less
    • Completion date: Jun 2027 to Dec 31, 2028
  3. Re-verified, no change to tracked fieldsv7
  4. Enrollment target: 41 to 87 Primary completion date: Jun 2024 to Jun 2026 · Completion date: Jun 2025 to Jun 2027 · Secondary endpoints: details revised at 2 of 4 entries · 1 morev6 Show 4 more changesShow less
    • Primary completion date: Jun 2024 to Jun 2026
    • Completion date: Jun 2025 to Jun 2027
    • Secondary endpoints: details revised at 2 of 4 entries
    • Site contacts updated at 1 of 2 sites
  5. Site details revised at 1 of 2 sitesv5
Show 3 earlier versionsHide 3 earlier versions
  1. Re-verified, no change to tracked fieldsv4
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jun 2021 to Apr 1, 2021 · Site details revised at 2 of 2 sitesv3 Show 2 more changesShow less
    • Start date changed from estimate of Jun 2021 to Apr 1, 2021
    • Site details revised at 2 of 2 sites
  3. Start date: Feb 2021 to Jun 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.
Trial Details
NCT Number NCT04683315
Lead Sponsor Medical College of Wisconsin
Conditions Pancreatic Cancer
Enrollment 84 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov